Spinal Cord Stimulators Market

Spinal Cord Stimulators Market: Overview

The Spinal Cord Stimulators Market is valued at USD 3.8 Bn in 2026 and is projected to reach USD 6.5 Bn, growing at a CAGR of 8% by 2033.The market size of Spinal Cord Stimulators Market was USD 1.9 billion in 2021, and it is projected to grow at a CAGR of 8.5 percent during the forecast period. The spinal cord stimulator (SCS), also called the dorsal column stimulator, is a neuromodulation tool implanted in the body to treat chronic pain. The gadget stops the brain from being able to perceive pain by releasing electric signals that block pain signals. It cures chronic pain by altering and inhibiting pain impulses before they reach the brain. According to the National Center for Biotechnology Information (NCBI), spinal cord stimulation therapy is not complete without electrical stimulation of the spinal cord’s dorsal surface, which lessens neuropathic pain.

According to the National Spinal Cord Injury Statistical Centre, the prevalence of chronic disorders has nearly doubled in recent years. Due to a rise in accidents and traumas associated with spinal operations and treatments, 54 cases of injuries per million people in the U.S. are reported as SCI each year. The market for spinal cord stimulators will grow during the projected period as chronic disorders become more prevalent. As more individuals become aware of the advantages of these technologies for treating pain, the market is anticipated to expand. The government's programs and policies that assist the elderly and the underprivileged in receiving care at affordable prices are major drivers of the market's expansion. The spinal cord stimulation market is expanding due to technological advancements, a wide range of healthcare facilities, and non-invasive procedures. The government's programs and policies are also a factor in the expansion. Due to ongoing research and development, manufacturers can create innovative technologies to meet demand. Paralyzed patients have demonstrated encouraging improvements from therapies like functional electrical stimulation (FES) and stem cell therapy. FES employs a computer and electrodes to give paralyzed muscles brief electronic pulses that stimulate and move them.

Implanting a spinal cord stimulator normally costs between $21,000 and $58,000. The price of the procedure also depends on whether the patient has private health insurance, public health insurance, or is paying out of pocket. In addition, the patient is responsible for all annual maintenance expenditures, including hardware, healthcare professionals' wages, pulse generator replacement, hospitalization fees, etc. This is anticipated to impede market expansion likely. CRPS symptoms can occur at any age, but according to the National Institute of Neurological Disorders and Stroke (NINDS), women are more likely than men to encounter them. 90.0% of the time, trauma and damage result in CRPS. Thus, the market's expansion is fueled by the rising number of people with chronic pain.

Spinal Cord Stimulators Market: COVID-19 Impact

The COVID-19 outbreak significantly affected elective and non-urgent treatments across the nation. The government decided to delay the operations, which would have slowed the market expansion for spinal cord stimulators (SCS) globally. The spinal cord stimulators (SCS) market faces several obstacles besides the COVID pandemic, such as product recalls, risks and side effects associated with the devices, and their high price.

Growing Elderly Population is Anticipated to Promote Spinal Cord Health Market

The growing elderly population is anticipated to accelerate the growth of the spinal cord stimulation industry. Due to the ongoing and growing demographic change in the average population age, several countries are experiencing difficulties. According to the Department of Economic and Social Affairs Population Division of the United Nations, in the next 30 years, the global population of those aged 60 and older will quadruple, and that of people aged 80 and older will triple. The World Health Organization predicts that by 2050, there will be around 1.5 billion individuals aged 65 or older, with developing nations accounting for most of this growth. Therefore, the market is being driven by the growing geriatric population, which is more susceptible to chronic ailments such as neurological disorders.

Ongoing Research and Development to Fuel Market Growth

The market is anticipated to grow and be able to service more opportunities over the forecast period due to the ongoing research and development in spinal cord stimulation. For instance, a team led by researchers from Brown University will develop and test an intelligent spinal interface to help people with spinal cord injuries regain their ability to move their limbs and control their bladder, according to an article published on October 3, 2019. This work will be made possible by a new grant of $6.3 million from the US Defense Advanced Research Projects Agency. Spinal cord stimulation can help paralyzed individuals regain voluntary movement and autonomic functioning, according to a February 1, 2019, publication.

The market growth is anticipated to be constrained by spinal cord stimulator implantation complications. However, difficulties are thought to affect 30% to 40% of patients, according to the American Society of Regional Anesthesia and Pain Medicine (ASRA), and can be categorized into two groups: device-related failure or biological causes. Additionally, the PriceGuide website estimates that stimulators typically cost $16,957. The cost of the most recent devices, made by Medtronic and Boston Scientific Corporation, is generally $19,000.

Spinal Cord Stimulators Market: Segment Overview

Rechargeable Products Dominated Segment Due to Cost-effectiveness

Rechargeable devices are anticipated to experience the quickest growth rate throughout the projection period due to their affordability, adaptability, and ability to control pain through wireless remote procedures. Such a gadget blocks neuropathic pain by gently electrically stimulating the spinal cord close to painful locations. It has a battery within that can be quickly changed by surgery. Additionally, new product releases by significant businesses and the rising number of patients with chronic and neuropathic pain propel the category forward. For instance, Boston Scientific introduced their Precision Novi implantable pulse generator spinal cord stimulator in June 2015. (IPG). The primary cell spinal cord stimulator implant is made to improve patient comfort and treat chronic pain, which is a major factor in the need for spinal procedures.

Complex Regional Pain Syndrome to Dominate Market Due to High Patient Count

Due to the large number of patients who suffer from chronic pain, the CRPS segment dominated the market for spinal cord stimulation devices. Changes in skin tone and temperature are additional symptoms of CRPS. All of these alterations result from aberrant microcirculation brought on by nerve injury that regulates blood flow and body temperature. Some people experience trauma or injury that results in soft tissue damage, sprains, fractures, limb immobility, or all of the above. Inflammatory substances present in the tissues also impact the immune system. Due to an increase in degenerative disc disease cases, the sector for degenerative disc disease is anticipated to develop quickly. When one or more discs between the spinal column and vertebrae degenerate or rupture, causing pain, it is primarily an age-related disorder. Technology developments and the creation of new products will probably help accelerate segment growth. For instance, the implantable neurostimulation device from Medtronic is intended to lessen chronic pain in the trunk or limbs. Failed back syndrome, post-laminectomy pain, peripheral causalgia, epidural fibrosis, failure disc surgery, and CRPS are the conditions it treats.

North America Dominated Market Due to High Technological Advancement

Due to increased chronic pain, failing back syndrome, and CRPS, North America dominated the global market in 2018 and is predicted to continue experiencing significant growth. Additionally, the presence of well-established healthcare facilities, the availability of highly qualified doctors, and raising awareness of spinal cord stimulation therapy will propel the regional market. Rapid market expansion is also anticipated due to the rapid adoption of technologically improved items.

Asia Pacific has the highest anticipated CAGR during the forecast period. Growth in the area is anticipated due to the large proportion of senior citizens and the rapid uptake of neuromodulation therapy. The rest of the world, which includes the Middle East and Africa, Latin America, and other areas, has tremendous growth potential and is anticipated to develop into a significant market. Factors like the increased prevalence of chronic back pain and the rising demand for minimally invasive therapies impact the market's expansion in other regions.

The Senza Omnia Spinal Cord Stimulation (SCS) System gave FDA approval on November 5, 2019, according to Nevro Corporation. It is the first and only SCS system made to administer Nevro's unique HF10 therapy, in addition to all other SCS systems currently on the market. GTX medical BV and NeuroRecovery Technologies Inc. ('NRT') joined on October 22, 2019, to form a global firm dedicated to discovering innovative neuromodulation therapies to enhance the functional recovery of patients with SCI.

Few of the players in the Spinal Cord Stimulators Market include 

• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• Nevro Corp.
• Stimwave Technologies
• Braun Melsungen AG
• Nuvectra Corporation
• Proteus Digital Health (now part of Medtronic)
• Colombus NeuroTech
• Cyberonics (LivaNova PLC)
• Minimally Invasive Neuromodulation, Inc.
• Nexstim Oy
• Saluda Medical Pty Ltd.
• Axonics Modulation Technologies
• Biotronik SE & Co. KG

By Product

• Rechargeable
• Non-rechargeable

By Disease Indication

• Failed Back Surgery Syndrome (FBSS)
• Degenerative Disc Disease (DDD)
• Complex Regional Pain Syndrome (CRPS)
• Arachnoiditis
• Others

By End User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa